调查：非洲的疟疾治疗药物整体“品质低劣”-凯发k8官网

africans suffering from ¹ may be getting sub-standard treatment, a study by us-based experts has suggested.

一组美国科学家经过研究得出结论，遭受疟疾之苦的非洲人可能接受着非正规的治疗。

the experts say their research threw up a disturbing trend

researchers from the pharmacopeia（药典，处方汇编） group found that between 26% and 44% of anti-malaria drugs in uganda, senegal（塞内加尔） and madagascar（马达加斯加） were of poor quality.

the group, conducting the study for the world health organization, said low-grade drugs were being used in both public and private health practices.

some 90% of malaria deaths in the world occur in africa.

the experts subjected 200 samples of anti-malaria drugs to quality-control testing in a us laboratory.

they found 44% of the drugs from senegal failed the testing, followed by 30% from madagascar and 26% from uganda.

patrick lukulay, director of the us government-funded pharmacopeia programme, said it was a "disturbing（烦扰的，令人不安的） trend".

"it is worrisome that almost all of the poor-quality data that was obtained was a result of ² amounts of active [ingredients材料，作料] or the presence of ³（杂质） in the product," he said.

the particular problem they identified was with artemisinin（青蒿素） -based drugs.

the chemical is one of the few ⁴ and effective treatments for malaria.

but the who's malaria programme chief robert newman said low-quality versions of the drug could increase resistance because they would not kill all of the ⁵.

"there are a number of things that need to be done - as a global community we need to support countries in strengthening their regulatory controls," mr newman said.

the researchers also studied drugs from seven other countries - cameroon（喀麦隆） , ethiopia, ghana（加纳） , kenya, malawi, nigeria and tanzania（坦桑尼亚） - but have not yet released data from those nations.

however, mr lukulay said ghana had already ⁶ more than 20 drugs from the market after seeing initial results.